Keregen Therapeutics

Keregen is a UK-based spin-out company from the School of Pharmacy, University College London. Founded in 2015, Keregen is focused on the discovery and development of first generation small-molecule therapies that slow or stop the progression of complex degenerative diseases where there is a clear unmet clinical need. The primary R&D program is directed to advance non-covalent Nrf2 activators to clinical candidate status for the treatment of Parkinson’s Disease. The company won the OneStart Europe competition in 2015, and has established a strong advisory network with expertise ranging from early drug discovery to scientific leadership and business development. Keregen is committed to excellence across all aspects of its work and is looking to secure initial investment to accelerate development activities.